Skip to content
1st Counsel – Lifestyle
Author:
Life Biosciences
Life Biosciences to Present First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies at Eyecelerator 2026
October 1, 2026
Life Biosciences Appoints Stephen Webster to Board of Directors
August 10, 2026
Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER‑100 for Optic Neuropathies
June 9, 2026
Life Biosciences Secures $80 Million Series D Financing
April 8, 2026